scholarly journals TU4. COMPREHENSIVE ANALYSIS OF OMICS DATA IDENTIFIED ADHD RELEVANT GENE NETWORKS

2021 ◽  
Vol 51 ◽  
pp. e96
Author(s):  
Judit Cabana-Domínguez ◽  
María Soler Artigas ◽  
Lorena Arribas ◽  
Laura Vilar-Ribó ◽  
Silvia Alemany ◽  
...  
2021 ◽  
Author(s):  
Adriaan-Alexander Ludl ◽  
Tom Michoel

Causal gene networks model the flow of information within a cell. Reconstructing causal networks from omics data is challenging because correlation does not imply causation. When genomics and transcriptomics data...


FEBS Open Bio ◽  
2021 ◽  
Author(s):  
Fan Liang ◽  
Chen Zhang ◽  
Hua Guo ◽  
San‐Hui Gao ◽  
Fu‐Ying Yang ◽  
...  

2021 ◽  
Author(s):  
Mai Adachi Nakazawa ◽  
Yoshinori Tamada ◽  
Yoshihisa Tanaka ◽  
Marie Ikeguchi ◽  
Kako Higashihara ◽  
...  

The identification of cancer subtypes is important for the understanding of tumor heterogeneity. In recent years, numerous computational methods have been proposed for this problem based on the multi-omics data of patients. It is widely accepted that different cancer subtypes are induced by different molecular regulatory networks. However, only a few incorporate the differences between their molecular systems into the classification processes. In this study, we present a novel method to classify cancer subtypes based on patient-specific molecular systems. Our method quantifies patient-specific gene networks, which are estimated from their transcriptome data. By clustering their quantified networks, our method allows for cancer subtyping, taking into consideration the differences in the molecular systems of patients. Comprehensive analyses of The Cancer Genome Atlas (TCGA) datasets applied to our method confirmed that they were able to identify more clinically meaningful cancer subtypes than the existing subtypes and found that the identified subtypes comprised different molecular features. Our findings show that the proposed method, based on a simple classification using the patient-specific molecular systems, can identify cancer subtypes even with single omics data, which cannot otherwise be captured by existing methods using multi-omics data.


2021 ◽  
Author(s):  
Anjun Ma ◽  
Xiaoying Wang ◽  
Cankun Wang ◽  
Jingxian Li ◽  
Tong Xiao ◽  
...  

We present DeepMAPS, a deep learning platform for cell-type-specific biological gene network inference from single-cell multi-omics (scMulti-omics). DeepMAPS includes both cells and genes in a heterogeneous graph to infer cell-cell, cell-gene, and gene-gene relations simultaneously. The graph attention neural network considers a cell and a gene with both local and global information, making DeepMAPS more robust to data noises. We benchmarked DeepMAPS on 18 datasets for cell clustering and network inference, and the results showed that our method outperforms various existing tools. We further applied DeepMAPS on a case study of lung tumor leukocyte CITE-seq data and observed superior performance in cell clustering, and predicted biologically meaningful cell-cell communication pathways based on the inferred gene networks. To improve the feasibility and ensure the reproducibility of analyzing scMulti-omics data, we deployed a webserver with multi-functions and various visualizations. Overall, we valued DeepMAPS as a novel platform of the state-of-the-art deep learning model in the single-cell study and can promote the use of scMulti-omics data in the community.


2019 ◽  
Vol 35 (24) ◽  
pp. 5182-5190 ◽  
Author(s):  
Luis G Leal ◽  
Alessia David ◽  
Marjo-Riita Jarvelin ◽  
Sylvain Sebert ◽  
Minna Männikkö ◽  
...  

Abstract Motivation Integration of different omics data could markedly help to identify biological signatures, understand the missing heritability of complex diseases and ultimately achieve personalized medicine. Standard regression models used in Genome-Wide Association Studies (GWAS) identify loci with a strong effect size, whereas GWAS meta-analyses are often needed to capture weak loci contributing to the missing heritability. Development of novel machine learning algorithms for merging genotype data with other omics data is highly needed as it could enhance the prioritization of weak loci. Results We developed cNMTF (corrected non-negative matrix tri-factorization), an integrative algorithm based on clustering techniques of biological data. This method assesses the inter-relatedness between genotypes, phenotypes, the damaging effect of the variants and gene networks in order to identify loci-trait associations. cNMTF was used to prioritize genes associated with lipid traits in two population cohorts. We replicated 129 genes reported in GWAS world-wide and provided evidence that supports 85% of our findings (226 out of 265 genes), including recent associations in literature (NLGN1), regulators of lipid metabolism (DAB1) and pleiotropic genes for lipid traits (CARM1). Moreover, cNMTF performed efficiently against strong population structures by accounting for the individuals’ ancestry. As the method is flexible in the incorporation of diverse omics data sources, it can be easily adapted to the user’s research needs. Availability and implementation An R package (cnmtf) is available at https://lgl15.github.io/cnmtf_web/index.html. Supplementary information Supplementary data are available at Bioinformatics online.


2018 ◽  
Author(s):  
Sara McArdle ◽  
Konrad Buscher ◽  
Erik Ehinger ◽  
Akula Bala Pramod ◽  
Nicole Riley ◽  
...  

AbstractBackgroundCohesive visualization and interpretation of hyperdimensional, large-scale -omics data is an ongoing challenge, particularly for biologists and clinicians involved in current highly complex sequencing studies. Multivariate studies are often better suited towards non-linear network analysis than differential expression testing. Here, we present PRESTO, a ‘PREdictive Stochastic neighbor embedding Tool for Omics’, which allows unsupervised dimensionality reduction of multivariate data matrices with thousands of subjects or conditions. PRESTO is intuitively integrated into an interactive user interface that helps to visualize the multidimensional patterns in genome-wide transcriptomic data from basic science and clinical studies.ResultsPRESTO was tested with multiple input omics’ platforms, including microarray and proteomics from both mouse and human clinical datasets. PRESTO can analyze up to tens of thousands of genes and shows no increase in processing time with a large number of samples or patients. In complex datasets, such as those with multiple time points, several patient groups, or diverse mouse strains, PRESTO outperformed conventional methods. Core co-expressed gene networks were intuitively grouped in clusters, or gates, after dimensionality reduction and remained consistent across users. Networks were identified and assigned to physiological and pathological functions that cannot be gleaned from conventional bioinformatics analyses. PRESTO detected gene networks from the natural variations among mouse macrophages and human blood leukocytes. We applied PRESTO to clinical transcriptomic and proteomic data from large patient cohorts and detected disease-defining signatures in antibody-mediated kidney transplant rejection, renal cell carcinoma, and relapsing acute myeloid leukemia (AML). In AML, PRESTO confirmed a previously described gene signature and found a new signature of 10 genes that is highly predictive of patient outcome.ConclusionsPRESTO offers an important integration of powerful bioinformatics tools with an interactive user interface that increases data analysis accessibility beyond bioinformaticians and ‘coders’. Here, we show that PRESTO out performs conventional methods, such as DE analysis, in multi-dimensional datasets and can identify biologically relevant co-expression gene networks. In paired samples or time points, co-expression networks could be compared for insight into longitudinal regulatory mechanisms. Additionally, PRESTO identified disease-specific signatures in clinical datasets with highly significant diagnostic and prognostic potential.


2016 ◽  
Vol 13 (9) ◽  
pp. 731-740 ◽  
Author(s):  
Stefka Tyanova ◽  
Tikira Temu ◽  
Pavel Sinitcyn ◽  
Arthur Carlson ◽  
Marco Y Hein ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Joseph R. Scarpa ◽  
Peng Jiang ◽  
Vance D. Gao ◽  
Martha H. Vitaterna ◽  
Fred W. Turek ◽  
...  

AbstractReduced NREM sleep in humans is associated with AD neuropathology. Recent work has demonstrated a reduction in NREM sleep in preclinical AD, pointing to its potential utility as an early marker of dementia. We test the hypothesis that reduced NREM delta power and increased tauopathy are associated with shared underlying cortical molecular networks in preclinical AD. We integrate multi-omics data from two extensive public resources, a human Alzheimer’s disease cohort from the Mount Sinai Brain Bank (N = 125) reflecting AD progression and a (C57BL/6J × 129S1/SvImJ) F2 mouse population in which NREM delta power was measured (N = 98). Two cortical gene networks, including a CLOCK-dependent circadian network, are associated with NREM delta power and AD tauopathy progression. These networks were validated in independent mouse and human cohorts. Identifying gene networks related to preclinical AD elucidate possible mechanisms associated with the early disease phase and potential targets to alter the disease course.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mai Adachi Nakazawa ◽  
Yoshinori Tamada ◽  
Yoshihisa Tanaka ◽  
Marie Ikeguchi ◽  
Kako Higashihara ◽  
...  

AbstractThe identification of cancer subtypes is important for the understanding of tumor heterogeneity. In recent years, numerous computational methods have been proposed for this problem based on the multi-omics data of patients. It is widely accepted that different cancer subtypes are induced by different molecular regulatory networks. However, only a few incorporate the differences between their molecular systems into the identification processes. In this study, we present a novel method to identify cancer subtypes based on patient-specific molecular systems. Our method realizes this by quantifying patient-specific gene networks, which are estimated from their transcriptome data, and by clustering their quantified networks. Comprehensive analyses of The Cancer Genome Atlas (TCGA) datasets applied to our method confirmed that they were able to identify more clinically meaningful cancer subtypes than the existing subtypes and found that the identified subtypes comprised different molecular features. Our findings also show that the proposed method can identify the novel cancer subtypes even with single omics data, which cannot otherwise be captured by existing methods using multi-omics data.


2019 ◽  
Vol 22 (5) ◽  
pp. 691-699 ◽  
Author(s):  
Quan Wang ◽  
Rui Chen ◽  
Feixiong Cheng ◽  
Qiang Wei ◽  
Ying Ji ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document